RSS   Newsletter   Contact   Advertise with us

Immunovaccine appoints Gabriela Rosu as CMO

Share on Twitter Share on LinkedIn
Staff Writer | Halifax, NS, Canada | November 3, 2016
ImmunovaccineNovember 3, 2016, Halifax, NS, Canada - Immunovaccine, a clinical stage vaccine and immunotherapy company, announced that Gabriela Rosu has been named the company's first chief medical officer.
Dr. Rosu brings to Immunovaccine more than 15 years of broad clinical and pharmaceutical industry experience. Most recently, she was appointed the Medical Science Liaison, Haematology Oncology, at Janssen Inc.

Prior to this position, Dr. Rosu served as the Global Medical Advisor in Haematology at Novo Nordisk. She held various positions of increasing responsibility in organizations including GlaxoSmithKline, Berlex, Celgene, and Lundbeck Canada.

Dr. Rosu started her career as Medical Doctor in Europe, practicing family medicine and emergency medicine after an internship in emergency surgery, obstetrics, and pediatrics.

Dr. Rosu received her Medical Doctor degree in 1995 from the Medical and Pharmaceutical University "Gr.T. Popa" in Iasi, Romania.